Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Tiziana Life Sciences

Nasdaq:TLSA
Snowflake Description

Worrying balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
TLSA
Nasdaq
£54M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. The last earnings update was 180 days ago. More info.


Add to Portfolio Compare Print
TLSA Share Price and Events
7 Day Returns
0%
NasdaqGM:TLSA
5.2%
US Biotechs
10.5%
US Market
1 Year Returns
-41.2%
NasdaqGM:TLSA
0%
US Biotechs
-11.5%
US Market
TLSA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Tiziana Life Sciences (TLSA) 0% -23.1% -38.6% -41.2% - -
US Biotechs 5.2% -6.5% -8.7% 0% 6.2% -10.4%
US Market 10.5% -15.4% -21.4% -11.5% 5.4% 18.1%
1 Year Return vs Industry and Market
  • TLSA underperformed the Biotechs industry which returned 0% over the past year.
  • TLSA underperformed the Market in United States of America which returned -11.5% over the past year.
Price Volatility
TLSA
Industry
5yr Volatility vs Market

Value

 Is Tiziana Life Sciences undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Tiziana Life Sciences is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Tiziana Life Sciences has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Tiziana Life Sciences. This is due to cash flow or dividend data being unavailable. The share price is $1.78.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Tiziana Life Sciences's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Tiziana Life Sciences's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:TLSA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in GBP £-0.05
AIM:TILS Share Price ** AIM (2020-03-27) in GBP £0.35
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.4x
United States of America Market PE Ratio Median Figure of 2,939 Publicly-Listed Companies 12.96x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Tiziana Life Sciences.

NasdaqGM:TLSA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AIM:TILS Share Price ÷ EPS (both in GBP)

= 0.35 ÷ -0.05

-7.67x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Tiziana Life Sciences is loss making, we can't compare its value to the US Biotechs industry average.
  • Tiziana Life Sciences is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Tiziana Life Sciences's expected growth come at a high price?
Raw Data
NasdaqGM:TLSA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -7.67x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.96x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Tiziana Life Sciences, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Tiziana Life Sciences's assets?
Raw Data
NasdaqGM:TLSA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in GBP £-0.02
AIM:TILS Share Price * AIM (2020-03-27) in GBP £0.35
United States of America Biotechs Industry PB Ratio Median Figure of 429 Publicly-Listed Biotechs Companies 2.53x
United States of America Market PB Ratio Median Figure of 5,148 Publicly-Listed Companies 1.26x
NasdaqGM:TLSA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AIM:TILS Share Price ÷ Book Value per Share (both in GBP)

= 0.35 ÷ -0.02

-14.74x

* Primary Listing of Tiziana Life Sciences.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Tiziana Life Sciences has negative assets, we can't compare the value of its assets to the US Biotechs industry average.

Next steps:

  1. Take a look at our analysis of TLSA’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Tiziana Life Sciences's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Biotechs industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Tiziana Life Sciences's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Tiziana Life Sciences has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Tiziana Life Sciences expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Tiziana Life Sciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
18.6%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Tiziana Life Sciences expected to grow at an attractive rate?
  • Unable to compare Tiziana Life Sciences's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Tiziana Life Sciences's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare Tiziana Life Sciences's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:TLSA Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:TLSA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (8 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in GBP Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:TLSA Future Estimates Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
NasdaqGM:TLSA Past Financials Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income *
2019-06-30 -5 -6
2019-03-31 -4 -6
2018-12-31 -3 -6
2018-09-30 -4 -6
2018-06-30 -5 -7
2018-03-31 -5 -7
2017-12-31 -6 -7
2017-09-30 -6 -8
2017-06-30 -7 -9
2017-03-31 -6 -8
2016-12-31 -5 -7
2016-09-30 -4 -7

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Tiziana Life Sciences is high growth as no earnings estimate data is available.
  • Unable to determine if Tiziana Life Sciences is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:TLSA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (8 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Tiziana Life Sciences Company Filings, last reported 8 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:TLSA Future Estimates Data
Date (Data in GBP Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
NasdaqGM:TLSA Past Financials Data
Date (Data in GBP Millions) EPS *
2019-06-30 -0.05
2019-03-31 -0.05
2018-12-31 -0.05
2018-09-30 -0.05
2018-06-30 -0.06
2018-03-31 -0.06
2017-12-31 -0.06
2017-09-30 -0.08
2017-06-30 -0.09
2017-03-31 -0.09
2016-12-31 -0.08
2016-09-30 -0.07

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Tiziana Life Sciences will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of TLSA’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Tiziana Life Sciences's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Tiziana Life Sciences's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Tiziana Life Sciences's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Tiziana Life Sciences has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Tiziana Life Sciences performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Tiziana Life Sciences's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Tiziana Life Sciences does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Tiziana Life Sciences's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Tiziana Life Sciences's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Tiziana Life Sciences's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Tiziana Life Sciences Company Filings, last reported 8 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:TLSA Past Revenue, Cash Flow and Net Income Data
Date (Data in GBP Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 -5.82 3.94 3.36
2019-03-31 -5.91 3.63 3.75
2018-12-31 -6.00 3.31 4.13
2018-09-30 -6.38 3.49 4.35
2018-06-30 -6.76 3.66 4.57
2018-03-31 -6.76 3.62 4.62
2017-12-31 -6.77 3.57 4.67
2017-09-30 -7.87 4.00 4.64
2017-06-30 -8.98 4.43 4.61
2017-03-31 -8.09 4.38 3.78
2016-12-31 -7.21 4.33 2.96
2016-09-30 -6.92 3.44 3.62
2016-06-30 -6.63 2.55 4.28
2016-03-31 -7.63 2.44 5.28
2015-12-31 -8.63 2.33 6.29
2015-09-30 -7.25 2.35 4.84
2015-06-30 -5.86 2.37 3.39
2015-03-31 -4.60 2.08 2.09
2014-12-31 -3.33 1.79 0.79

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Tiziana Life Sciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Tiziana Life Sciences has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Tiziana Life Sciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess Tiziana Life Sciences's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Tiziana Life Sciences has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Tiziana Life Sciences's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Tiziana Life Sciences's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Tiziana Life Sciences's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Tiziana Life Sciences's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Tiziana Life Sciences's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Tiziana Life Sciences has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Tiziana Life Sciences Company Filings, last reported 8 months ago.

NasdaqGM:TLSA Past Debt and Equity Data
Date (Data in GBP Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 -2.99 0.25 0.45
2019-03-31 -2.99 0.25 0.45
2018-12-31 0.41 0.24 4.17
2018-09-30 0.41 0.24 4.17
2018-06-30 -3.22 0.64 0.07
2018-03-31 -3.22 0.64 0.07
2017-12-31 -1.68 0.23 0.05
2017-09-30 -1.68 0.23 0.05
2017-06-30 0.06 0.00 2.01
2017-03-31 0.06 0.00 2.01
2016-12-31 3.31 0.23 4.70
2016-09-30 3.31 0.23 4.70
2016-06-30 7.47 0.22 8.28
2016-03-31 7.47 0.22 8.28
2015-12-31 8.50 0.22 8.90
2015-09-30 8.50 0.22 8.90
2015-06-30 6.37 0.21 6.96
2015-03-31 6.37 0.21 6.96
2014-12-31 1.78 0.21 2.27
  • Tiziana Life Sciences has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Tiziana Life Sciences's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Tiziana Life Sciences has less than a year of cash runway based on current free cash flow.
  • Tiziana Life Sciences has less than a year of cash runway if free cash flow continues to grow at historical rates of 4.1% each year.
X
Financial health checks
We assess Tiziana Life Sciences's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Tiziana Life Sciences has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Tiziana Life Sciences's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Tiziana Life Sciences dividends.
If you bought $2,000 of Tiziana Life Sciences shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Tiziana Life Sciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Tiziana Life Sciences's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:TLSA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1949 Stocks 3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:TLSA Future Dividends Estimate Data
Date (Data in £) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Tiziana Life Sciences has not reported any payouts.
  • Unable to verify if Tiziana Life Sciences's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Tiziana Life Sciences's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Tiziana Life Sciences has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Tiziana Life Sciences's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Tiziana Life Sciences afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Tiziana Life Sciences has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Tiziana Life Sciences's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Shailu Shailubhai
COMPENSATION £1,575,754
AGE 61
TENURE AS CEO 12.2 years
CEO Bio

Dr. Kunwar Shailubhai, also known as Shailu, Ph.D., M.B.A., has been Chief Executive Officer, Chief Scientific Officer and Executive Director at Tiziana Life Sciences PLC since 2008. Dr. Shailubhai had been Director of Rasna Therapeutics, Inc. since August 2016. Dr. Shailubhai was a Co-Founder of Synergy Pharmaceuticals Inc., and served as its Chief Scientific Officer/Chief Science Officer from July 9, 2008 to May 23, 2017 and Executive Vice President from November 21, 2015 to May 23, 2017. Dr. Shailubhai served as the Senior Vice President of Drug Discovery at Synergy Pharmaceuticals Inc. from March April 6, 2004 to July 2008. He served as Head of Research and Development at Callisto Pharmaceuticals, Inc. (Formerly, Webtronics Inc.) and also served its Executive Vice President of Research and Development from May 2003 to March 2004 and Executive Vice President. From 2001 to April 2003, Dr. Shailubhai served as the Vice President for Drug Discovery of Synergy Pharmaceuticals Inc., where he was chiefly responsible for the preclinical development of GC-C agonist program for drugs to treat colon cancer and GI inflammation. Dr. Shailubhai had been Chief Executive Officer of Rasna Therapeutics, Inc. since April 14, 2017 until January 31, 2020. He served as Chief Scientific Officer of Pawfect Foods Inc. since July 2008. From 1993 to 2000, he served at Monsanto Life Sciences Company as Group Leader of the Cancer Chemoprevention Group and was involved in several cancer research projects. He has extensive experience within the life sciences sector, drawing experience in research and development of drug candidates for treatment of gastrointestinal disorders, inflammatory diseases and cancers. He has been a Non-Executive Director of OKYO Pharma Limited (formerly West African Minerals Corporation) since July 6, 2017. Dr. Shailubhai served as a Non-Executive Director at Tiziana Life Sciences PLC since January 22, 2015 until June 14, 2017. He served as a Director of GenSignia Life Sciences Inc. Dr. Shailubhai's pioneering research programme culminated in the development of the drug Trulance™ (plecanatide) which received FDA approval in January 2017 for the treatment of adults with chronic idiopathic constipation. A supplemental new drug application has been submitted for FDA review of Trulance for the treatment of adults with irritable bowel syndrome with constipation (IBS-C). He has more than 20 issued patents and over 50 peer-reviewed publications. He previously served as a Senior Staff Fellow at the National Institutes of Health and as an Assistant Professor at the University of Maryland. Dr. Shailubhai holds Ph.D. in Microbiology from 1976 to 1984 from The Maharaja Sayajirao University of Baroda, India and an M.B.A. in General Administration from the University of Missouri, St. Louis from 1999 to 2001.

CEO Compensation
  • Shailu's compensation has increased whilst company is loss making.
  • Shailu's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Tiziana Life Sciences management team in years:

5.3
Average Tenure
60.5
Average Age
  • The average tenure for the Tiziana Life Sciences management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Gabriele Marco Cerrone

TITLE
Founder & Executive Chairman
COMPENSATION
£652K
AGE
47

Shailu Shailubhai

TITLE
CEO, Chief Scientific Officer & Executive Director
COMPENSATION
£2M
AGE
61
TENURE
12.2 yrs

Tiziano Lazzaretti

TITLE
Chief Financial Officer
COMPENSATION
£141K
AGE
60
TENURE
4 yrs

Andrea Brancale

TITLE
Scientific Founder

Richard Clarkson

TITLE
Scientific Founder

Andy Westwell

TITLE
Scientific Founder

Yaron Ilan

TITLE
Chief Medical Officer

P. Cooper

TITLE
Secretary

Phil Boyd

TITLE
Consultant
TENURE
4.8 yrs

Napoleone Ferrara

TITLE
Chairman of Scientific Advisory Board & Consultant
AGE
63
TENURE
5.8 yrs
Board of Directors Tenure

Average tenure and age of the Tiziana Life Sciences board of directors in years:

4.3
Average Tenure
62
Average Age
  • The tenure for the Tiziana Life Sciences board of directors is about average.
Board of Directors

Gabriele Marco Cerrone

TITLE
Founder & Executive Chairman
COMPENSATION
£652K
AGE
47
TENURE
5.9 yrs

Shailu Shailubhai

TITLE
CEO, Chief Scientific Officer & Executive Director
COMPENSATION
£2M
AGE
61
TENURE
12.2 yrs

Napoleone Ferrara

TITLE
Chairman of Scientific Advisory Board & Consultant
AGE
63
TENURE
5.8 yrs

Willy Simon

TITLE
Non-Executive Director
COMPENSATION
£51K
AGE
68
TENURE
4.3 yrs

Kevan Herold

TITLE
Member of Scientific Advisory Board
TENURE
4.2 yrs

Howard Weiner

TITLE
Member of Scientific Advisory Board
AGE
74
TENURE
4.2 yrs

Arun Sanyal

TITLE
Member of Scientific Advisory Board
TENURE
3 yrs

Gregor Charles MacRae

TITLE
Non-Executive Director
AGE
56
TENURE
0.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Tiziana Life Sciences's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Tiziana Life Sciences has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. The company’s product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such as non-alcoholic steatohepatitis, Crohn’s disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma. It also develops TZLS-501, a human anti-interleukin-6 receptor monoclonal antibody that is in pre-clinical development. The company was founded in 2013 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited.

Details
Name: Tiziana Life Sciences PLC
TLSA
Exchange: NasdaqGM
Founded: 2013
£66,608,427
153,321,181
Website: http://www.tizianalifesciences.com
Address: Tiziana Life Sciences PLC
55 Park Lane,
London,
Greater London, W1K 1NA,
United Kingdom
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AIM TILS Ordinary Shares London Stock Exchange AIM Market GB GBP 25. Apr 2014
NasdaqGM TLSA SPONSORED ADS Nasdaq Global Market US USD 20. Nov 2018
Number of employees
Current staff
Staff numbers
10
Tiziana Life Sciences employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 03:41
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2019/04/04
Last earnings filing: 2019/09/30
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.